1.37
price down icon9.27%   -0.14
pre-market  Vorhandelsmarkt:  1.43   0.06   +4.38%
loading
Schlusskurs vom Vortag:
$1.51
Offen:
$1.5
24-Stunden-Volumen:
2.07M
Relative Volume:
0.51
Marktkapitalisierung:
$113.68M
Einnahmen:
$78.12M
Nettoeinkommen (Verlust:
$-153.22M
KGV:
-0.6683
EPS:
-2.05
Netto-Cashflow:
$-136.90M
1W Leistung:
-23.03%
1M Leistung:
+11.38%
6M Leistung:
-65.32%
1J Leistung:
-84.05%
1-Tages-Spanne:
Value
$1.36
$1.56
1-Wochen-Bereich:
Value
$1.36
$1.829
52-Wochen-Spanne:
Value
$1.12
$8.585

Editas Medicine Inc Stock (EDIT) Company Profile

Name
Firmenname
Editas Medicine Inc
Name
Telefon
617-401-9000
Name
Adresse
11 HURLEY ST., CAMBRIDGE, MA
Name
Mitarbeiter
226
Name
Twitter
@editasmed
Name
Nächster Verdiensttermin
2025-03-05
Name
Neueste SEC-Einreichungen
Name
EDIT's Discussions on Twitter

Vergleichen Sie EDIT mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
EDIT
Editas Medicine Inc
1.37 113.68M 78.12M -153.22M -136.90M -2.05
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
502.92 129.14B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
680.61 74.41B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
581.21 35.31B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
241.75 31.30B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
254.57 27.35B 3.32B -860.46M -1.04B -8.32

Editas Medicine Inc Stock (EDIT) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2024-12-16 Herabstufung JP Morgan Neutral → Underweight
2024-12-13 Herabstufung Chardan Capital Markets Buy → Neutral
2024-12-13 Herabstufung Stifel Buy → Hold
2024-12-13 Herabstufung Truist Buy → Hold
2024-12-11 Herabstufung Wells Fargo Overweight → Equal Weight
2024-11-25 Herabstufung BofA Securities Buy → Underperform
2024-11-06 Hochstufung Evercore ISI In-line → Outperform
2024-11-04 Herabstufung Raymond James Outperform → Mkt Perform
2024-08-08 Hochstufung BofA Securities Neutral → Buy
2024-05-09 Hochstufung Morgan Stanley Underweight → Equal-Weight
2023-10-24 Hochstufung Citigroup Neutral → Buy
2023-10-18 Hochstufung JP Morgan Underweight → Neutral
2023-10-17 Herabstufung Cantor Fitzgerald Overweight → Neutral
2023-09-29 Hochstufung Stifel Hold → Buy
2023-06-12 Hochstufung Raymond James Mkt Perform → Outperform
2023-02-01 Eingeleitet Cantor Fitzgerald Overweight
2022-12-13 Eingeleitet Citigroup Neutral
2022-12-06 Fortgesetzt Credit Suisse Neutral
2022-11-18 Herabstufung Credit Suisse Outperform → Neutral
2022-11-18 Herabstufung Oppenheimer Outperform → Perform
2022-09-29 Eingeleitet BofA Securities Neutral
2021-10-19 Eingeleitet SVB Leerink Mkt Perform
2021-09-24 Eingeleitet Stifel Hold
2021-09-10 Hochstufung Oppenheimer Perform → Outperform
2021-08-09 Hochstufung Truist Hold → Buy
2021-08-05 Hochstufung Evercore ISI Underperform → Outperform
2021-06-04 Fortgesetzt Robert W. Baird Outperform
2021-05-04 Eingeleitet RBC Capital Mkts Sector Perform
2021-04-16 Eingeleitet Goldman Sell
2021-03-22 Eingeleitet Credit Suisse Outperform
2021-03-01 Herabstufung Barclays Overweight → Equal Weight
2021-02-26 Herabstufung Truist Buy → Hold
2021-01-19 Herabstufung Morgan Stanley Equal-Weight → Underweight
2021-01-07 Herabstufung Raymond James Outperform → Mkt Perform
2020-12-10 Hochstufung Wells Fargo Equal Weight → Overweight
2020-11-03 Eingeleitet Robert W. Baird Underperform
2020-06-18 Fortgesetzt SunTrust Buy
2020-02-21 Eingeleitet Wells Fargo Equal Weight
2019-04-12 Eingeleitet Evercore ISI Outperform
2018-10-10 Eingeleitet Guggenheim Neutral
2018-09-21 Eingeleitet Raymond James Outperform
2018-05-15 Bestätigt Chardan Capital Markets Buy
2018-02-13 Eingeleitet CLSA Underperform
2018-01-23 Hochstufung SunTrust Hold → Buy
2017-07-14 Eingeleitet SunTrust Hold
2017-03-28 Eingeleitet Chardan Capital Markets Buy
2016-08-10 Hochstufung Jefferies Hold → Buy
2016-06-02 Eingeleitet Jefferies Hold
2016-02-29 Eingeleitet JMP Securities Mkt Outperform
2016-02-29 Eingeleitet JP Morgan Neutral
2016-02-29 Eingeleitet Morgan Stanley Equal-Weight
Alle ansehen

Editas Medicine Inc Aktie (EDIT) Neueste Nachrichten

pulisher
Mar 13, 2025

Editas Medicine Reports Progress in Gene Editing - TipRanks

Mar 13, 2025
pulisher
Mar 13, 2025

Gene Editing Market Future Business Opportunities 2025-2032 | - openPR

Mar 13, 2025
pulisher
Mar 13, 2025

Here's Why Editas Medicine (NASDAQ:EDIT) Must Use Its Cash Wisely - Yahoo Finance

Mar 13, 2025
pulisher
Mar 12, 2025

Editas Medicine’s SWOT analysis: gene editing firm pivots strategy amid stock volatility - Investing.com

Mar 12, 2025
pulisher
Mar 12, 2025

Editas Medicine, Inc. (NASDAQ:EDIT) Given Consensus Rating of “Hold” by Analysts - Defense World

Mar 12, 2025
pulisher
Mar 12, 2025

Editas Medicine, Inc. (NASDAQ:EDIT) Given Consensus Rating of "Hold" by Analysts - MarketBeat

Mar 12, 2025
pulisher
Mar 12, 2025

Editas Medicine Inc.’s Stock Volatility: Key Risks and Investor Considerations - TipRanks

Mar 12, 2025
pulisher
Mar 10, 2025

Editas Medicine at Leerink’s Global Healthcare Conference: In Vivo Focus By Investing.com - Investing.com Canada

Mar 10, 2025
pulisher
Mar 10, 2025

Editas Medicine (NASDAQ:EDIT) Issues Earnings Results - MarketBeat

Mar 10, 2025
pulisher
Mar 09, 2025

Editas Medicine Stock Slides After-Hours On Bigger-Than-Expected Q4 Loss, But Retail Bulls Eye M&A Potential - MSN

Mar 09, 2025
pulisher
Mar 09, 2025

Editas Q4 Loss Wider Than Expected, Revenues Fall Y/Y, Stock Down - MSN

Mar 09, 2025
pulisher
Mar 09, 2025

Editas Medicine (NASDAQ:EDIT) Posts Quarterly Earnings Results, Misses Expectations By $0.16 EPS - MarketBeat

Mar 09, 2025
pulisher
Mar 07, 2025

Sell Rating for Editas Medicine Amid Strategic Shift and Competitive Pressures - TipRanks

Mar 07, 2025
pulisher
Mar 07, 2025

Buy Rating for Editas Medicine Driven by Promising Preclinical Advances and Strong Financial Position - TipRanks

Mar 07, 2025
pulisher
Mar 07, 2025

Editas Medicine, Inc. to Host Earnings Call - ACCESS Newswire

Mar 07, 2025
pulisher
Mar 07, 2025

Editas Medicine (EDIT) Stock Price, News & Analysis - MarketBeat

Mar 07, 2025
pulisher
Mar 06, 2025

Global Genome Editing Market to Grow Rapidly at a CAGR ~13% by 2032 | DelveInsight - GlobeNewswire Inc.

Mar 06, 2025
pulisher
Mar 06, 2025

Editas Medicine (EDIT) Reports Q4 Loss, Misses Revenue Estimates - MSN

Mar 06, 2025
pulisher
Mar 06, 2025

Editas: Q4 Earnings Snapshot - Midland Daily News

Mar 06, 2025
pulisher
Mar 05, 2025

Editas Medicine Announces Fourth Quarter and Full Year 2024 Results and Business Updates - GlobeNewswire

Mar 05, 2025
pulisher
Mar 05, 2025

Editas Medicine Inc reports results for the quarter ended December 31Earnings Summary - TradingView

Mar 05, 2025
pulisher
Mar 05, 2025

EDITAS MEDICINE Earnings Results: $EDIT Reports Quarterly Earnings - Nasdaq

Mar 05, 2025
pulisher
Mar 05, 2025

Editas Medicine Inc Reports Q4 2024 Loss of $0.55 EPS and $30.6 Million Revenue, Missing Estimates - GuruFocus.com

Mar 05, 2025
pulisher
Mar 05, 2025

Editas Medicine shares fall as Q4 earnings miss estimates - Investing.com

Mar 05, 2025
pulisher
Mar 05, 2025

EDITAS MEDICINE, INC. Q4 Loss Increases, Misses Estimates - Nasdaq

Mar 05, 2025
pulisher
Mar 05, 2025

Editas Medicine reports Q4 EPS (55c), consensus (33c) - TipRanks

Mar 05, 2025
pulisher
Mar 05, 2025

Can Editas Medicine's Strategic Shift to In Vivo Editing Reverse Its $237M Annual Loss? - StockTitan

Mar 05, 2025
pulisher
Mar 04, 2025

Editas Medicine Q4 2024 Earnings Preview - MSN

Mar 04, 2025
pulisher
Mar 03, 2025

Editas Medicine Inc expected to post a loss of 36 cents a shareEarnings Preview - TradingView

Mar 03, 2025
pulisher
Mar 02, 2025

Top 5 CRISPR Companies To Invest In (March 2025) - Securities.io

Mar 02, 2025
pulisher
Mar 02, 2025

Reviewing Aligos Therapeutics (NASDAQ:ALGS) & Editas Medicine (NASDAQ:EDIT) - Defense World

Mar 02, 2025
pulisher
Feb 28, 2025

Editas Medicine Q1 2024 Earnings Preview - MSN

Feb 28, 2025
pulisher
Feb 27, 2025

Editas Medicine (EDIT) Projected to Post Earnings on Wednesday - MarketBeat

Feb 27, 2025
pulisher
Feb 26, 2025

Editas: The high-risk, high-reward gene editing pioneer - BioCentury

Feb 26, 2025
pulisher
Feb 25, 2025

Peering Into Editas Medicine's Recent Short Interest - Benzinga

Feb 25, 2025
pulisher
Feb 25, 2025

Editas Medicine to Announce Fourth Quarter/Full Year 2024 - GlobeNewswire

Feb 25, 2025
pulisher
Feb 24, 2025

Editas Medicine to Announce Fourth Quarter/Full Year 2024 Financial Results and to Participate in Investor Conferences in March - The Manila Times

Feb 24, 2025
pulisher
Feb 24, 2025

Editas Medicine to Announce Q4 2024 Financial Results and Upcoming Investor Conference Participation - Nasdaq

Feb 24, 2025
pulisher
Feb 24, 2025

Editas Medicine to Announce Fourth Quarter/Full Year 2024 Financial Results and to Participate - The Bakersfield Californian

Feb 24, 2025
pulisher
Feb 24, 2025

Access Editas Medicine's Full March Lineup: Earnings Plus 3 Major Healthcare Conferences - StockTitan

Feb 24, 2025
pulisher
Feb 19, 2025

Editas Medicine, Inc. (NASDAQ:EDIT) Receives $7.00 Average PT from Analysts - MarketBeat

Feb 19, 2025

Finanzdaten der Editas Medicine Inc-Aktie (EDIT)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$75.07
price up icon 1.39%
$305.39
price down icon 0.55%
$19.19
price down icon 3.62%
$32.68
price down icon 0.52%
$97.47
price down icon 2.84%
biotechnology ONC
$254.57
price up icon 1.89%
Kapitalisierung:     |  Volumen (24h):